1341 PharmaBio Delegate Booklet

More documents

Recommendations

Info

1341 PharmaBio Delegate Booklet 28/11/07 14:41 Page 8 Speakers Dr Geoffrey Guy Executive Chairman GW Pharmaceuticals Plc Dr Guy has over twenty years experience in pharmaceutical development covering new chemical entities, biotechnology products, plant-based medicines, controlled drugs and drug delivery systems. Dr Guy has been the physician in charge of over 200 clinical studies including first dose in man, pharmacokinetics, pharmacodynamics, dose-ranging, controlled clinical trials and large scale multi-centred studies and clinical surveys. In 1981 Dr Guy moved into the pharmaceutical sector and joined Pierre Fabre Laboratories in Castres, France where he subsequently became UK Clinical Trials Co-ordinator. In 1984 Dr Guy moved to become first Director of Clinical Development and then Assistant Medical Director of Napp Laboratories in Cambridge. Between 1983 and 1985 Dr Guy founded and was a Partner in Datalink Biomedical, a company established to exploit a computerised digital lung function machine. In 1985 Dr Guy founded the drug delivery company Ethical Holdings plc, of which he was Chief Executive Officer and Chairman (from 1991), and led the company to its NASDAQ flotation in 1993 before leaving in 1997. Dr Guy received 3i’s “Venturer of the Year” award in the Science and technology category. Through Ethical he also pursued a policy of investment in other pharmaceutical opportunities which led to the founding of Phytopharm plc, the plant medicines company listed on the UK stock exchange. Dr Guy was, until 1997, Chairman of Phytopharm the objective of which was to develop plant-based medicines derived from traditional Chinese medicine. Ethical also invested in the jet injector company Antares Pharma Inc (formerly Medi-Ject Corporation) in 1994 and Dr Guy was a Director of the company from November 1993 until January 2001. In 1997 the Home Office granted Dr Guy licenses to cultivate, possess and supply cannabis for research purposes and in 1998 GW Pharmaceuticals Plc was established through which to operate these licenses. The objective of GW was, and remains, to develop a portfolio of non-smoked, prescription cannabis-based medicines and the Company has been carrying out a number of Phase I, II and III clinical trials investigating the use of these medicines in multiple sclerosis, neuropathic pain, spinal cord injury and cancer pain. Simon Hammett UK Life Sciences and Health Care Practice Leader Deloitte Simon Hammett is a Partner in the Consulting practice at Deloitte. He is a senior partner within our UK Strategy practice and also leads the EMEA Growth and Innovation team. He focuses on Pharmaceuticals and Manufacturing and has worked extensively with leading global pharmaceutical and medical companies including: GlaxoSmithKline, Pfizer, British Oxygen Company and Roche. Mr Hammett is very active in client service and focuses on competitive strategy development, strategy implementation including enterprise-wide transformation, and CRM/sell-side solutions. He joined the firm from business school in 1993 with 6 years’ previous management experience. His experience included research management, new product development, new ventures, technical sales and enterprise strategy. –– 8 –– Mr Andrew Jack Pharmaceutical Correspondent Financial Times Andrew Jack is a journalist with the Financial Times, currently based in London. He joined the newspaper in 1990, and worked as a correspondent in London, Paris and Moscow. Since 2005, he has covered pharmaceuticals and healthcare. He is author of the books Inside Putin’s Russia (Granta/Oxford University Press, 2005) and The French Exception (Profile Books/Editions Odile Jacob, 2001). He graduated from Cambridge University, studied at Harvard University and worked for New York City Government and as a freelance consultant and writer before joining the FT. Dr Panos Kanavos Lecturer, International Healthcare Policy London School of Economics Panos Kanavos is Senior Lecturer in International Health Policy in the Department of Social Policy, Merck Fellow in Pharmaceutical Economics and Head of the Medical Technology Research Unit at LSE Health. He is also Visiting Professor at the University of Lausanne. He has acted as advisor to a number of international governmental and non-governmental organisations, including the World Bank, the World Health Organisation and the Organisation for Economic Co-operation and Development, the American Association for Retired Persons and Ministries of Health in over 21 transition and developing countries. He is currently participating in the European Pharmaceutical Forum as advisor to the European Commission. His research interests comprise comparative health policy and health care reform; pharmaceutical economics and policy; quality in health care; and the socio-economic determinants of health. Mr Nick Lowcock Managing Director Warburg Pincus Nicholas J. Lowcock leads the firm’s healthcare investing activities in Europe. Mr Lowcock was with the Boston Consulting Group before he joined Warburg Pincus in 1994. He previously worked in the pharmaceutical industry in the United Kingdom. Mr Lowcock received a B.A. (first class) in experimental psychology from Oxford University and an M.B.A. with distinction from The Wharton School at the University of Pennsylvania. He is a member of the board of trustees of Project Hope UK, a charity devoted to improving healthcare in developing nations. Mr Lowcock is a director of Archimedes, Eurand, Euromedic and ProStrakan.
1341 PharmaBio Delegate Booklet 28/11/07 14:41 Page 9 Dr Louise Makin Chief Executive Officer BTG plc Dr Louise Makin is currently Chief Executive Officer of BTG plc, which develops novel pharmaceuticals and other medical technologies. She was appointed Chief Executive Officer in October 2004 and has led the turnaround and strategic repositioning of the company. Previously, Dr Makin was President of the Biopharmaceuticals Division of Baxter Healthcare Europe, after having joined Baxter in 2000 as Vice President, Strategy & Business Development Europe. Prior to Baxter, she spent 13 years with ICI and English China Clay. Dr Makin holds an MA in Natural Sciences, a PhD in Metallurgy from the University of Cambridge, and an MBA. She is also a Non Executive Director on the Board of Premier Foods plc, Chairman of the Advisory Board of Lancaster University Business School and a Trustee of the Engineering Development Trust. Dr Lynn Marks Senior Vice President, Infectious Diseases Medicine Development Centre, GlaxoSmithKline Dr Marks received his medical degree from the University of South Alabama College of Medicine and is Board Certified in Internal Medicine and Infectious Diseases. He joined SmithKline Beecham in 1993 as Associate Director and later Director, Anti-infectives Clinical Research, Development, and Medical Affairs. He then moved to the Consumer Healthcare Division where he held the positions of Worldwide Medical Director, Rx to OTC Switch and then, Vice President and Director, Worldwide Medical, Regulatory, and Toxicology. Later he returned to Pharma as, Vice President, Global Commercial Strategy, Infectious Diseases and subsequently became Senior Vice President, Infectious Diseases, Medicine Development Centre. Prior to joining industry, Dr Marks was with the University of South Alabama College of Medicine, where he held the positions of Assistant Professor of Medicine in the Division of Infectious Diseases and Adjunct Assistant Professor in the Department of Microbiology and Immunology as well as the Department of Pharmacology. His NIH supported research centred on the molecular genetics of Rickettsia. –– 9 –– Mr John Mayo CBE Managing General Partner Celtic Pharma John Mayo graduated in Economics from Loughborough University and qualified as a Chartered Accountant. As an investment banker in the eighties and early nineties, John Mayo advised among others on the spin-off of Zeneca Group plc by ICI plc; the privatisation of Irish Life ($750 million) and the IPO of Wellcome plc ($1.5 billion). In 1997, he initiated the merger between Zeneca and Astra, and in September 1997 John left to join The General Electric Company plc as Finance Director. He has founded and grown several businesses including Beehive Capital LLP, and Salisbury Associates. During the last 10 years he has served as a non-executive director on the boards of the following public companies: Schlumberger, Alstom, Newcastle United, and Pentland. He has also served on the following UK public bodies: The Takeover Panel; The Confederation of British Industry’s Companies Committee; Her Majesty’s Treasury Public Sector Productivity Panel; and the FTSE Policy Committee. In 1999, John Mayo was made a Commander of the British Empire (CBE), in recognition of his services to British industry. John Mayo is a founder of Celtic Pharma, a global private equity firm focused on the pharmaceutical industry. He is a UK citizen and is based in London. Mr John D MacCarthy Vice President, Client Thought Leadership IMS Health ® Mr MacCarthy is Vice President, Client Thought Leadership at IMS Health and is responsible for spearheading the development of the company's thought leadership based approach to customer engagement globally. He works extensively with clients in both the US and Europe. His background includes over 20 years experience in the pharmaceutical industry gained in a career that began at Beecham Research Laboratories (now part of GSK) in 1977. He later joined Pharmacia UK in 1984 where he spent a number of years in roles in Sales, Marketing Management and Corporate Development. In 1995, John was appointed V.P. Strategy for Pharmacia & Upjohn Europe, based in Paris. He was a member of the UK integration teams following the mergers of Kabi Vitrum with Pharmacia and of Kabi Pharmacia with Farmitalia Carlo Erba, and a member of the global integration team during the Pharmacia and Upjohn merger. Since joining IMS Health in 1998, Mr MacCarthy has also been responsible for creating the sales force effectiveness suite of offerings in Europe and has been a major contributor to the development of the continuum of information, analytics and consulting services in the region. He has supported client management teams in the USA and most major European markets to develop action plans to drive measurable improvement in the performance of key brands. In one case, in a project covering over 10 countries, an improvement in brand performance of over $40m was achieved. Mr MacCarthy holds a Masters Degree in Business Administration and a Bachelors degree in Applied Chemistry.
Page 1 and 2: 1341 PharmaBio Delegate Booklet 28/
Page 7: 1341 PharmaBio Delegate Booklet 28/

1341 PharmaBio Delegate Booklet

Create successful ePaper yourself

Delete template?

Save as template?